- Aclaris’ stock added triple gains on January 19, on the back of a successful phase-2 trial of its oral inflammatory drug, ATI-450.
- Dare’s shares have soared by 86 per cent YTD, led by its research and development success.
- Both biopharmaceutical stocks have yielded three-digit growth in the last three months.
Stocks of Aclaris Therapeutics, Inc. (ACRS:US or NASDAQ: ACRS) skyrocketed over 220 per cent on Tuesday (January 19) after the company announced the positive trial result for Oral ATI-450, an immuno-inflammatory disease drug. The biotech firm also plans to allow the underwriters a 30-day option to buy its additional 15 per cent common shares. The stocks are
Stocks of another biotech company Dare Bioscience Inc. (DARE:US or NASDAQ: DARE) climbed over 63 per cent on Tuesday. The company had announced successful Phase 3 trial result for DARE-BVFREE, a bacterial vaginosis medicine.
By Wednesday morning (10:51 ET), Aclaris Therapeutics stock gained 8.6 per cent while Dare Bioscience soared by 32 per cent.
Let us delve into these two trending biopharma stocks:
Aclaris Therapeutics, Inc. (ACRS:US or NASDAQ: ACRS)
Current Stock Price: US$ 20.46
The biotech company operates in clinical-stage pharmaceutical R&D in the United States. It is specialized in dermatology.
The pharma company’s shares are up 305 per cent in the last three months. It has delivered a one-year return of over 906 per cent, with a present price-to-book ratio of 19.82.
The healthcare stock’s hundred million shares changed hands on Tuesday.
In the third quarter of 2020, Aclairs’ R&D costs were US$ 6.9 million against US$ 16.2 million in Q3 2019. Its total revenue surged to US$ 1.4 million in Q3 2020 from US$ 1.0 million in Q3 2019.
Dare Bioscience Inc. (DARE:US or NASDAQ: DARE)
Current Stock Price: US$ 2.36
This US-based healthcare company develops therapies for women's reproductive wellbeing.
DARE stock has yielded almost 86 per cent growth year-to-date (YTD), with an average trading volume of 5 million in the last 10 days. The stock surged over 129 per cent in the last three months.
The biotech company has total listed shares outstanding of 41.6 million. Due to heavy trading on January 19, its trading volume soared to 46.56 million.
Dare Bioscience’s R&D expenses were around US$ 6.2 million for Q3 2020, more than triple surge year-over-year (YoY) from nearly US$ 2.0 million for Q3 2019. The rise was because of increased costs associated with R&D activities for DARE-BV1.